{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105942","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.507920+00:00","generated_at":"2026-05-17T00:40:58.652609+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M","bullets":["Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.","Raised 2025 revenue guidance to $845-865M from $820-860M.","Record quarterly patient adds ~500, total ~8,100 average narcolepsy patients.","Cash & investments $778M; generated $106M cash flow in Q3.","Pipeline: pitolisant HD IND filed; Phase 3 narcolepsy/IH starts Q4; orexin-2 agonist first subject Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105942","json":"https://secwatch.observer/filing/0001104659-25-105942.json","markdown":"https://secwatch.observer/filing/0001104659-25-105942.md","text":"https://secwatch.observer/filing/0001104659-25-105942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/0001104659-25-105942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:40:58.652609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}